Qlife Holding AB (SE:QLIFE)
:QLIFE
Top Page
Qlife Holding AB
(QLIFE)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr2.00
▼(-33.55% Downside)
Action:ReiteratedDate:02/18/26
The score is primarily weighed down by very weak financial performance, including collapsed revenue, ongoing losses, and continued operating cash burn alongside negative equity. Technicals are more neutral than bearish but do not show strong upside momentum, and valuation remains unattractive/unclear due to losses and no dividend support.
Positive Factors
Deleveraging
Material debt reduction substantially lowers near-term refinancing pressure and interest burden, improving financial flexibility. For a cash-burning biotech, lower nominal debt extends runway and reduces insolvency risk, making follow-on financing or operational restructuring easier to execute.
Negative Factors
Collapsed revenue
A precipitous drop to a very small revenue base undermines scale economics and product-market fit, making it harder to cover fixed R&D and commercial costs. Persistent minimal revenue limits ability to demonstrate sustainable growth and weakens leverage for partnerships or commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Deleveraging
Material debt reduction substantially lowers near-term refinancing pressure and interest burden, improving financial flexibility. For a cash-burning biotech, lower nominal debt extends runway and reduces insolvency risk, making follow-on financing or operational restructuring easier to execute.
Read all positive factors
Qlife Holding AB (QLIFE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr62.40M
Dividend YieldN/A
Average Volume (3M)97.19K
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue Growth376.81%
EPS Growth97.95%
CountrySE
Employees3
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.18
Shares Outstanding31,359,041
10 Day Avg. Volume81,486
30 Day Avg. Volume97,188
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-4.74
Price to Sales (P/S)109.73
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-126.16
Revenue Forecast (FY)kr116.00M
Qlife Holding AB Business Overview & Revenue Model
Company Description
Qlife Holding AB (QLIFE) is a biotechnology company based in Sweden, specializing in the development of advanced diagnostic tools aimed at improving patient care and health outcomes. The company focuses on innovative solutions in the healthcare se...
How the Company Makes Money
QLIFE generates revenue primarily through the sale of its diagnostic products and services. The company offers its proprietary testing platforms to hospitals, clinics, and laboratories, which pay for the devices and associated consumables. Additio...
Qlife Holding AB Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
7
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 324.00K | 50.00K | 244.00K | 17.99M | 39.61M |
| Gross Profit | -19.38M | -158.00K | -6.31M | -10.75M | 44.54M |
| EBITDA | -18.11M | -12.46M | -150.50M | -78.05M | -35.13M |
| Net Income | -20.56M | -55.98M | -159.96M | -93.14M | -38.80M |
Balance Sheet | |||||
| Total Assets | 9.63M | 11.64M | 39.05M | 192.65M | 193.44M |
| Cash, Cash Equivalents and Short-Term Investments | 1.42M | 2.71M | 1.66M | 14.55M | 73.46M |
| Total Debt | 8.55M | 8.70M | 20.25M | 52.44M | 4.72M |
| Total Liabilities | 17.14M | 13.07M | 62.17M | 101.50M | 30.26M |
| Stockholders Equity | -7.51M | -1.43M | -23.12M | 91.15M | 132.50M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -54.17M | -62.64M | -90.67M | -52.82M |
| Operating Cash Flow | -15.60M | -37.37M | -41.80M | -47.73M | -26.05M |
| Investing Cash Flow | 0.00 | -16.80M | -20.84M | -42.94M | -26.77M |
| Financing Cash Flow | 14.30M | 55.23M | 49.00M | 32.73M | 106.02M |
Qlife Holding AB Technical Analysis
Neutral
3.01
Price Trends
2.06
Negative
2.04
Negative
2.68
Negative
Market Momentum
-0.02
Positive
47.98
Neutral
32.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:QLIFE, the sentiment is Neutral. The current price of 3.01 is above the 20-day moving average (MA) of 1.99, above the 50-day MA of 2.06, and above the 200-day MA of 2.68, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 47.98 is Neutral, neither overbought nor oversold. The STOCH value of 32.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:QLIFE.
Qlife Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | kr62.40M | -1.73 | 437.24% | ― | 376.81% | 97.95% | |
44 Neutral | kr46.85M | -2.89 | -60.56% | ― | 163.12% | 30.50% | |
44 Neutral | kr56.90M | -8.36 | ― | ― | ― | ― | |
43 Neutral | kr51.24M | -1.14 | -50.21% | ― | ― | -108.64% | |
43 Neutral | kr134.97M | -1.96 | ― | ― | ― | ― |
* Healthcare Sector Average
SE:QLIFE
Qlife Holding AB
1.99
-1.21
-37.73%
SE:SPEC
SpectraCure AB
0.09
-0.70
-88.68%
SE:LXB
Luxbright AB
0.36
-0.49
-57.65%
SE:HEART
Scandinavian Real Heart AB
13.50
-1.35
-9.07%
SE:SDOS
ScandiDos AB
1.00
-0.43
-30.21%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.